aTYR Pharma: Pay

aTYR Pharma paid its 3 named executives $6.1M in total in FY2025 (Dec). CEO Sanjay S. Shukla, M.D., M.S. was paid $3.5M of that.

Pay$100 in the stock at the end of FY22 → $36
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Sanjay S. Shukla, M.D., M.S.President and CEO
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years
Jill BroadfootChief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years
Nancy E. DenyesGeneral Counsel
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 4 peers with pay on file was $6.4M. The CEO of aTYR Pharma was paid $3.5M, 46% below the median.

  1. 1Scholar Rock Holding
  2. 2Altimmune
  3. 3Savara
  4. 4Trevi Therapeutics
  5. 5aTYR Pharma
  6. 6Acelyrin, Inc.Not disclosed
  7. 7Alector, Inc.Not disclosed
  8. 8Allakos Inc.Not disclosed
  9. 9Fortress Biotech, Inc.Not disclosed
  10. 10Gossamer Bio, Inc.Not disclosed
  11. 11Immunic, Inc.Not disclosed
  12. 12Jasper Therapeutics, Inc.Not disclosed
  13. 13KalVista Pharmaceuticals, Inc.Not disclosed
  14. 14Kezar Life Sciences, Inc.Not disclosed
  15. 15Longboard Pharmaceuticals, Inc.Not disclosed
  16. 16Pliant Therapeutics, Inc.Not disclosed
  17. 17X4 Pharmaceuticals, Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.